Dr. Welling on Incorporating Immunotherapy Into HCC Paradigm – OncLive
|
Dr. Welling on Incorporating Immunotherapy Into HCC Paradigm
OncLive Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agents will eventually fit into the paradigm of hepatocellular … |
